These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 241494)

  • 41. [The pharmacokinetics of 1-(4-cyclohexylureidophenoxy)-2-hydroxy-3-tert-butylaminopropane (talinolol, Cordanum, 02-115) 2. Excretion, blood level and distribution of the 14C-labeled compound in the rat].
    Klemm W; Wenzel A
    Pharmazie; 1975 Oct; 30(10):675-7. PubMed ID: 695
    [No Abstract]   [Full Text] [Related]  

  • 42. [Morphological changes in the ciliary epithelium after subconjunctival administration of befunolol (beta-adrenergic blocker)].
    Hiramatsu K; Yamashita H
    Nippon Ganka Gakkai Zasshi; 1982; 86(8):1051-65. PubMed ID: 6129790
    [No Abstract]   [Full Text] [Related]  

  • 43. L-653,328: an ocular hypotensive agent with modest beta receptor blocking activity.
    Sugrue MF; Gautheron P; Grove J; Mallorga P; Viader MP; Baldwin JJ; Ponticello GS; Varga SL
    Invest Ophthalmol Vis Sci; 1988 May; 29(5):776-84. PubMed ID: 2896641
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Further studies on the tumor-initiating activity of the beta-blocker DL-ZAMI 1305.
    Pacces N; Braga M; Zavanella T; Presta M; Ragnotti G
    Toxicol Pathol; 1986; 14(4):470-6. PubMed ID: 2880384
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibition in vitro of yeast DNA polymerase I activity by beta-blockers.
    Presta M; Riboni L; Ragnotti G
    Biosci Rep; 1982 Jan; 2(1):55-62. PubMed ID: 6120725
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vitro and in vivo DNA damage of male and female rat liver nuclei by oncogenic and nononcogenic beta blockers.
    Presta M; Mazzocchi C; Ziliani S; Ragnotti G
    J Natl Cancer Inst; 1983 Apr; 70(4):747-52. PubMed ID: 6132020
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Determination of propranolol and carvedilol in urine samples using a magnetic polyamide composite and LC-MS/MS.
    Ballesteros-Esteban T; Reyes-Gallardo EM; Lucena R; Cárdenas S; Valcárcel M
    Bioanalysis; 2016 Oct; 8(20):2115-23. PubMed ID: 27593542
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Studies on local anaesthetic and antiarrhythmic actions of 1-isopropylamino-3-(4-indanoxy)-2-propanol HCI (USVC-6524), a new beta-adrenoceptor antagonist.
    Madan BR; Vyas DS
    Indian J Physiol Pharmacol; 1973; 17(3):227-34. PubMed ID: 4151008
    [No Abstract]   [Full Text] [Related]  

  • 49. Simultaneous determination of (R)- and (S)-celiprolol in human plasma and urine: high-performance liquid chromatographic assay on a chiral stationary phase with fluorimetric detection.
    Hartmann C; Krauss D; Spahn H; Mutschler E
    J Chromatogr; 1989 Nov; 496(2):387-96. PubMed ID: 2575621
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of short-acting beta-adrenergic blocker on B-type natriuretic peptide at early stage of postresuscitation in rabbits.
    Li X; Li PJ; He YF; Zeng H; Li ZL; Zhang ZY; Cao W; Yang L
    Chin Med J (Engl); 2006 May; 119(10):864-7. PubMed ID: 16732990
    [No Abstract]   [Full Text] [Related]  

  • 51. Elimination of nadolol by patients with renal impairment.
    Herrera J; Vukovich RA; Griffith DL
    Br J Clin Pharmacol; 1979; 7 Suppl 2(Suppl 2):227S-231S. PubMed ID: 37878
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tissue distribution of exaprolol in rat.
    Faberová V; Trnovec T; Zemánek M; Bezek S; Durisová M; Tomcíková O
    Eur J Drug Metab Pharmacokinet; 1985; 10(1):11-3. PubMed ID: 2863149
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [The pharmacokinetics of 1-(4-cyclohexylureidophenoxy)-2-hydroxy-3-tert-butylaminopropane (talinolol, Cordanum, 02-115). 1. Blood levels in dogs].
    Femmer K; Klemm W; Nürnberger H
    Pharmazie; 1975 Oct; 30(10):673-5. PubMed ID: 694
    [No Abstract]   [Full Text] [Related]  

  • 54. Clinical-pharmacological evaluation of a new beta blocker, GYKI-41099 (tobanum).
    Török E; Istvánffy M; Halmágyi M; Wagner M; Csukás M
    Int J Clin Pharmacol Ther Toxicol; 1980; 18(5):200-7. PubMed ID: 6104634
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Morphological changes in the ciliary epithelium after instillation of 1% befunolol (beta-adrenergic blocker)].
    Hiramatsu K; Yamashita H; Uyama M
    Nippon Ganka Gakkai Zasshi; 1984 Feb; 88(2):251-65. PubMed ID: 6147071
    [No Abstract]   [Full Text] [Related]  

  • 56. [Experimental anti-arrhythmic effects of a new beta-adrenergic receptor blocking agent, dl-l-(tert. butylamino)-3-[(2-propinyloxy)phenoxy]2-propanol hydrochloride (dl Kö 1400-Cl)].
    Matsubara I; Hashimoto K; Katano Y; Tsukada T; Matsuda H
    Nihon Yakurigaku Zasshi; 1976 Jul; 72(5):557-71. PubMed ID: 11153
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Blockade of central beta-adrenergic receptors by tazolol (1-isopropylamino-3-(2-thiazoloxy)-2-propanol).
    Skolnick P; Stalvey LP; Daly JW
    Life Sci; 1977 Dec; 21(11):1655-63. PubMed ID: 23478
    [No Abstract]   [Full Text] [Related]  

  • 58. Pharmacological properties of an extremely selective beta 1-adrenoceptor antagonist, 2-[4-[3-(tert-Butylamino)-2-hydroxypropoxy] phenyl]-3-methyl-6-methoxy-4(3H)-quinazolinone [+/-)HX-CH 44 BS).
    Daemmgen JW; Engelhardt G; Pelzer H
    Arzneimittelforschung; 1985; 35(1A):383-90. PubMed ID: 2859033
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Isolation, identification and in vitro synthesis of conjugates of penbutolol and its metabolites.
    Lehr KH; Damm P; Fehlhaber HW; Hajdù P
    Arzneimittelforschung; 1987 Nov; 37(11):1222-4. PubMed ID: 3440029
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Butofilolol pharmacokinetics in chronic renal insufficiency.
    Jeanniot JP; Houin G; Ledudal P; Cautreels W; Giudicelli CP; Tillement JP
    Int J Clin Pharmacol Res; 1984; 4(3):165-73. PubMed ID: 6149194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.